Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing-Reference-Cited by-同舟云学术

Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing

Published:2022-01-28 Issue:8 Volume:128 Page:1649-1657
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Reizine Natalie M.¹²^ORCID,Danahey Keith²³,Truong Tien M.¹²,George David²⁴,House Larry K.¹²,Karrison Theodore G.⁵,Wijk Xander M. R.²⁴⁶,Yeo Kiang‐Teck J.²⁴⁶,Ratain Mark J.¹²⁶,O’Donnell Peter H.¹²⁶^ORCID

Affiliation:

1. Section of Hematology/Oncology Department of Medicine University of Chicago Medical Center and Biological Sciences Chicago Illinois

2. Center for Personalized Therapeutics University of Chicago Chicago Illinois

3. Center for Research Informatics University of Chicago Chicago Illinois

4. Department of Pathology University of Chicago Medical Center and Biological Sciences Chicago Illinois

5. Department of Public Health Sciences University of Chicago Chicago Illinois

6. Committee on Clinical Pharmacology and Pharmacogenomics University of Chicago Chicago Illinois

Funder

NIH Clinical Center

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34104

Reference49 articles.

1. Cancer Statistics, 2021

2. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study

3. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology

4. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT 15 Genotypes: 2018 Update

5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-06

2. Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology;Journal of Clinical Oncology;2024-04-01

3. Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities;Drug Metabolism and Disposition;2024-01-29

4. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer;Expert Opinion on Drug Metabolism & Toxicology;2024-01-12

5. Implementation of pharmacogenomics testing for precision medicine;Critical Reviews in Clinical Laboratory Sciences;2023-09-30